超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國Epitomics 
美國Epitomics公司成立于2001年9月，與加州大學舊金山分校(UCSF)及芝加哥LOYOLA大學聯(lián)手開發(fā)出新型雜交瘤技術，擁有兔單克隆抗體（RabMabs）技術的全球專利，是國際上唯一一家擁有兔類單抗技術的生物技術公司。目前，利用此技術開發(fā)生產(chǎn)的高質量兔單抗產(chǎn)品，已廣泛應用于科研和診斷領域。

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics.

Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the Company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle.

The Company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The Company is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.